If anything has characterized the professions in the past decade it is the proliferation of guidelines, targets and standards. These are beginning to act as a kind of scaffoldÐ in both senses, some fearÐfor medical practice. In this modern setting it is increasingly important, for clinicians, patients and payers, to know the consequences of clinical intervention. However, guessing what is on the`other side of the hill' is arguably not good enough, and ad hoc clinical encounters are not the best basis for predictable clinical outcomes 1 . In renal medicine, my own specialty, the quantitative components of clinical practice are particularly suitable for audit purposes, in regard to both treatment processes and outcomes. It is not surprising that some of the issues in predicting clinical outcomes are being explored ®rst in a renal context.
AIMING POINTS
Current documents recommend a variety of renal standards, for blood pressure, biochemistry, dialysis dose and so on 2,3 . A minimum or maximum value is declared typically as a limit for desirable clinical results. When outcome data are presentedÐfor example, in the UK Renal Registry (UKRR) reportÐthey are given as distributions for any given renal unit patient cohort. Depending on where the standard limits have been pitched for the variable there will be an overlap, since the outcome distributions have an inevitable dispersion (standard deviation, SD) ( Figure 1 ). Minimizing the dispersion of results is desirable for clinical and economic reasons, but, contrary to intuition, the mere declaration of a`target' value does not necessarily narrow the eventual distribution. Much effort may be required to do so, even in areas of technical control such as dialysis 4 . One may of course choose to aggregate the mean values of repeated measurements in individual patients, so as to narrow any given rangeÐa tactic that has been little debated. For a majority of values to fall on the desired side of the declared minimum/ maximum, the mean/median of the outcome distribution must to a varying degree exceed the guideline value. Thè target' aiming point for management therefore also needs to exceed the standard limit and the necessary mean by some uncertain amount. This`something in excess' of desirable results does not have a name, nor do we have a simple phrase to convey the necessity (except perhaps Robert Browning's`a man's reach should exceed his grasp'). The excess allows for the inevitable underachievements of practice, whether due to problems of patient ascertainment or inadequacy of delivered treatment. Perhaps because we are always opposing a pathological`pressure', it is usual for the factors that impede therapy to far outweigh those that facilitate it. In other words, our processes do not lead to failure or success at random, but are biased to Figure 1 Any set of results will be aligned in relation to a declared standard minimum or maximum, overlapping to a variable extent because of the inevitable dispersion of results. In this example the distribution overlaps a desired minimum value in a particular way. The mathematical consequence of any Gaussian curve divided at one standard deviation below the mean is to give 85% of readings above the dividing value. This allows some prediction of the characteristics necessary to comply at the 85% level with any given`standard' value (Ref. 7, by permission, Oxford University Press)
under-performance 5±7 . Both under-aspiration and miscellaneous practical factors underlie this phenomenon, as demonstrated in studies of dialysis dosing in the US 8, 9 .
DEFINING OUTCOME DISTRIBUTIONS
The more sophisticated`standards' may take this into account by specifying that physician compliance need only involve, say, 85% of the patient group. Such an allowance still implies that the distribution of results must assume a certain position in relation to the limit. As shown in Figure  1 , when results are Gaussian in distribution 85% will be above a given minimum if that is one SD below the mean, a property of classical statistics. This gives a lead to achieving the standard, as demonstrated in Box 1 (Nos 1±3). Such speci®c positioning of the distribution of results is dif®cult to achieve by design. The unthinking use of`target' values seems to lead to distributions that straddle the limit, as illustrated by the ESAM study of renal anaemia, where the minimum haemoglobin standard of 11 g/dL is also the outcome mean value 10 . Perhaps clinical effort falls away once the value is achieved, or perhaps pathological pressure' causes an undesirable drift in the population under stable therapy. It remains the case that the`target' aiming point towards which effort must be applied is uncertain in current systemsÐto what pressure below 140/ 80 mmHg should one pursue values in order to achieve a high rate of correspondence with a 140/80 maximum? Moreover, even in the best studies of treatment ef®cacy the declared treatment aims may prove unachievable 11 . Studies from the UKRR suggest another way to assess the`over-achievement' necessary for complete correspondence with`standards'. The outcome distributions for haemoglobin and dialysis dose, measured as urea reduction ratio, are Gaussian, with rather uniform dispersion of data (SDs). This allows the use of data from several renal units to explore the relation of mean/median and per cent satisfaction with a guideline minimum/maximum. A plot of the mean/median of each unit against the per cent compliance with any standard min/max indicates the mean/ median of the necessary distribution ( Figure 2) 12 . In this case a median unit haemoglobin of about 11.5 g/dL would be necessary to comply with 85% above 10 g/dL. An essential caveat is that this re¯ects current procedures, since a systematic narrowing of outcome ranges would give different necessary values.
ACHIEVING PARTICULAR DISTRIBUTIONS
Having decided what speci®c distribution, how should clinicians then proceed? Can we manage a patient cohort so as to produce a predictable distribution of results? In other words, can we aim at averages? The usual technique of declaring progressively more extreme`aiming-points' (say lower blood pressure or higher haemoglobin) may drive outcome distributions in the desired direction, but this is scarcely a predictable methodology. There could be other approaches, but it begs a method that is more explicit than an ad hoc approach to individual patients (the usual gold standard of practice 7 ). Sociology exists partly because people tend to behave differently in groups than as individuals, so we might reasonably ask whether patient groups might be handled in the whole, rather than as simply an aggregate`sum of parts'. Since we manage individual patients by shifting treatment doses to adjust towards desirable results, what would be the effect of doing the same systematically to a large population? This implies ®xed intervention pointsÐin the case of renal anaemia, say, onè threshold' value below the desired mean/median and onè ceiling' value above. This has been attempted in a large unselected dialysis cohort over several years for the management of renal anaemia with erythropoietin and iron and seems to produce reliable distributions that can be made to comply with`standard' recommendations 13±15 (see Box 1, No. 4) . As it happens, UKRR data show that in practice we can always know what is`on the other side of the hill', month on month, year on year. The outcome of clinical management is very stable when re¯ected in large groups, and shifts only with major changes of procedure or case-mix. What are required are treatment technologies to allow the determination of distributions in response to best practice guidelines 16 .
IMPLICATIONS FOR GUIDELINES
We do not have the means of predicting the distribution of results unless we adopt some new approaches, where thè aiming-point' is likely to be less important than the threshold/ceiling values for intervention. These need to be de®ned through clinical research in each case. The further implication is that recommendations should in future not only contain the desirable limits but also attempt to de®ne the features of the anticipated outcome distributions in mean/median and range. They should also, for best, indicate the costs and safety of achieving them, in case of hazard at the extremes of predictable outcome ranges and futile expenditure in the course of over-compensation for under-achievement 17 . This re¯ects the fact that guidelines and standards are the basis of treatment policies that should be subject to explicit risk analysis before implementation. Although the fanfares of the guideline culture were not entirely without justi®cation, it appears that we know better where to go than how to get there. This is partly because ef®cacy studies (can it be done?) greatly exceed effectiveness studies (does it work?) 18 . Declarations of ideal intent imply the need for research into calibrated clinical interventions, to put the achievement of clinical outcomes into a predictable, safe and cost-effective mould 19 . The fusion of clinical aspiration, basic medical science and statistics in this exercise represents a novel response to the recent call for integration of these elements of medicine 20 .
